Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Breast Cancer Research and Treatment|February 16, 2021
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registryJosé P Leone, Bernardo A Leone, Nabihah Tayob, et al.
The International Journal of Biological Markers|May 21, 2016
Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimenJulieta Leone, Juan E Perez, Maria E Dominguez, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2023
Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' toolJosé P Leone, Noah Graham, Julieta Leone, et al.
Breast Cancer Research and Treatment|April 24, 2021
Factors associated with late risks of breast cancer-specific mortality in the SEER registryJosé P Leone, Carlos T Vallejo, Michael J Hassett, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2022
Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' toolJosé P Leone, Noah Graham, Sara M Tolaney, et al.
NPJ Breast Cancer|April 4, 2024
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancerPaolo Tarantino, Julieta Leone, Carlos T Vallejo, et al.
JAMA Network Open|April 9, 2026
Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast CancerJosé P Leone, Julieta Leone, Pietro De Placido, et al.
Breast Cancer Research and Treatment|December 12, 2013
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experienceJosé Pablo Leone, Julieta Leone, Carlos Teodoro Vallejo, et al.
Pageof 3